NeoX™, bringing the
good fight to bacteria
NeoX™ is Lixa's potent antibiofilm platform technology.
It prevents biofilms from forming and breaks down existing biofilm formations. NeoX™ clears the way for antimicrobials to reach unprotected bacteria.
aims to provide solutions for persistant and resistant infections
How NeoX™ can rescue antimicrobials from AMR
Within the human and animal antimicrobial market, biofilm disruption therapies, such as NeoX™, are expected to break the ongoing cycle of antimicrobial resistance by dismantling the biofilm. This enables existing or new antibiotics to clear otherwise persistent bacterial infections.
NeoX™, includes a proprietary, non-antibiotic, small antibiofilm molecule that disrupts both long-standing and immature bacterial biofilms. Promising results to date suggest that NeoX™ is scalable across multiple different infections and contaminations, and is compatible with other antimicrobials (including bacteriostatic and bactericidal).
The lead development candidate, NeoX-101, is in preparation to enter clinical development.
